Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK.
Humans
Female
Aged
Aged, 80 and over
Male
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Pandemics
Cohort Studies
Prospective Studies
COVID-19
/ epidemiology
Dose Fractionation, Radiation
Neoplasm Recurrence, Local
/ pathology
United Kingdom
/ epidemiology
Neoplasm Staging
Treatment Outcome
COVID-19
Chemotherapy
hypofractionation
lung cancer
radiotherapy
reduced fractionation
Journal
Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
17
03
2023
revised:
13
06
2023
accepted:
17
07
2023
medline:
11
9
2023
pubmed:
29
7
2023
entrez:
28
7
2023
Statut:
ppublish
Résumé
Previous work found that during the first wave of the COVID-19 pandemic, 34% of patients with lung cancer treated with curative-intent radiotherapy in the UK had a change to their centre's usual standard of care treatment (Banfill et al. Clin Oncol 2022;34:19-27). We present the impact of these changes on patient outcomes. The COVID-RT Lung database was a prospective multicentre UK cohort study including patients with stage I-III lung cancer referred for and/or treated with radical radiotherapy between April and October 2020. Data were collected on patient demographics, radiotherapy and systemic treatments, toxicity, relapse and death. Multivariable Cox and logistic regression were used to assess the impact of having a change to radiotherapy on survival, distant relapse and grade ≥3 acute toxicity. The impact of omitting chemotherapy on survival and relapse was assessed using multivariable Cox regression. Patient and follow-up forms were available for 1280 patients. Seven hundred and sixty-five (59.8%) patients were aged over 70 years and 603 (47.1%) were female. The median follow-up was 213 days (119, 376). Patients with stage I-II non-small cell lung cancer (NSCLC) who had a change to their radiotherapy had no significant increase in distant relapse (P = 0.859) or death (P = 0.884); however, they did have increased odds of grade ≥3 acute toxicity (P = 0.0348). Patients with stage III NSCLC who had a change to their radiotherapy had no significant increase in distant relapse (P = 0.216) or death (P = 0.789); however, they did have increased odds of grade ≥3 acute toxicity (P < 0.001). Patients with stage III NSCLC who had their chemotherapy omitted had no significant increase in distant relapse (P = 0.0827) or death (P = 0.0661). This study suggests that changes to radiotherapy and chemotherapy made in response to the COVID-19 pandemic did not significantly affect distant relapse or survival. Changes to radiotherapy, namely increased hypofractionation, led to increased odds of grade ≥3 acute toxicity. These results are important, as hypofractionated treatments can help to reduce hospital attendances in the context of potential future emergency situations.
Identifiants
pubmed: 37507280
pii: S0936-6555(23)00263-7
doi: 10.1016/j.clon.2023.07.005
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e593-e600Subventions
Organisme : Department of Health
ID : BRC-1215-20007
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C147/A18083
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C147/ A25254
Pays : United Kingdom
Informations de copyright
Copyright © 2023. Published by Elsevier Ltd.